Bicara Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-92.33	-68	-51.99	-37.85
Depreciation & Amortization	0.06	0.06	0.02	0.01
Asset Writedown & Restructuring Costs	-	-	0.57	-
Stock-Based Compensation	9.7	7.4	1.9	0.81
Other Operating Activities	-0	-0.08	13.5	-
Change in Accounts Payable	6.8	2.64	-8.66	5.87
Change in Other Net Operating Assets	-12.5	-16.77	-0.96	-0.92
Operating Cash Flow	-88.27	-74.75	-45.63	-32.08
Capital Expenditures	-0.07	-0.07	-0.59	-0.19
Sale of Property, Plant & Equipment	-	0.06	-	-
Investing Cash Flow	-0.07	-0.01	-0.59	-0.19
Issuance of Common Stock	334.35	334.03	0.15	0.16
Financing Cash Flow	334.35	334.03	272.5	31.7
Net Cash Flow	246.02	259.27	226.28	-0.57
Free Cash Flow	-88.34	-74.82	-46.21	-32.27
Free Cash Flow Per Share	-2.92	-4.45	-79.66	-75.20
Cash Income Tax Paid	0.07	-	-	0
Levered Free Cash Flow	-	-53.72	-32.5	-
Unlevered Free Cash Flow	-	-53.72	-32.5	-
Change in Net Working Capital	-	9.61	8.9	-

Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q